How to buy NextCure stock | $7.85

NextCure, Inc is a biotechnology business based in the US. NextCure shares (NXTC) are listed on the NASDAQ and all prices are listed in US Dollars. NextCure employs 90 staff and has a market cap (total outstanding shares value) of 0.00.

NextCure stock price (NASDAQ: NXTC)

Use our graph to track the performance of NXTC stocks over time.

NextCure shares at a glance

• Key figures

Information last updated 2021-07-28.

Latest market close	$7.85
52-week range	$6.82 - $14.40
50-day moving average	$7.80
200-day moving average	$9.87
Wall St. target price	$19.38
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.92

Buy NextCure shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy NextCure stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of NextCure, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NextCure price performance over time

Historical closes compared with the close of $7.85 from 2021-05-28

1 week (2021-07-22)	N/A
1 month (2021-07-02)	-1.75%
3 months (2021-04-30)	-10.49%
6 months (2021-01-29)	N/A

1 year (2020-07-29)	N/A
2 years (2019-07-29)	N/A
3 years (2018-07-29)	N/A
5 years (2016-07-29)	N/A

NextCure financials

Gross profit TTM	$-24,176,000
Return on assets TTM	-13.14%
Return on equity TTM	-20.58%
Profit margin	0%
Book value	$10.11
Market capitalisation	$200.4 million

TTM: trailing 12 months

Shorting NextCure shares

There are currently 1.0 million NextCure shares held short by investors – that's known as NextCure's "short interest". This figure is 50.1% up from 687,766 last month.

There are a few different ways that this level of interest in shorting NextCure shares can be evaluated.

NextCure's "short interest ratio" (SIR)

NextCure's "short interest ratio" (SIR) is the quantity of NextCure shares currently shorted divided by the average quantity of NextCure shares traded daily (recently around 348653.37837838). NextCure's SIR currently stands at 2.96. In other words for every 100,000 NextCure shares traded daily on the market, roughly 2960 shares are currently held short.

However NextCure's short interest can also be evaluated against the total number of NextCure shares, or, against the total number of tradable NextCure shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NextCure's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 NextCure shares in existence, roughly 40 shares are currently held short) or 0.0591% of the tradable shares (for every 100,000 tradable NextCure shares, roughly 59 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NextCure.

Find out more about how you can short NextCure stock.

NextCure share dividends

We're not expecting NextCure to pay a dividend over the next 12 months.

NextCure share price volatility

Over the last 12 months, NextCure's shares have ranged in value from as little as $6.82 up to $14.4. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NextCure's is -0.514. This would suggest that NextCure's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, NextCure has bucked the trend.

NextCure overview

NextCure, Inc. , a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; and NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. NextCure, Inc. has a license agreement with Yale University.

Frequently asked questions

What percentage of NextCure is owned by insiders or institutions?
Currently 10.085% of NextCure shares are held by insiders and 52.673% by institutions. How many people work for NextCure?
Latest data suggests 90 work at NextCure. When does the fiscal year end for NextCure?
NextCure's fiscal year ends in December. Where is NextCure based?
NextCure's address is: 9000 Virginia Manor Road, Beltsville, MD, United States, 20705 What is NextCure's ISIN number?
NextCure's international securities identification number is: US65343E1082 What is NextCure's CUSIP number?
NextCure's Committee on Uniform Securities Identification Procedures number is: 65343E108